FilingReader Intelligence
Hybio advances semaglutide partnership with SanSheng Mendy
August 19, 2025 at 05:40 PM UTC•By FilingReader AI
Hybio Pharmaceutical has signed manufacturing and supply agreements with Zhejiang SanSheng Mendy Pharmaceutical for semaglutide injection production.
The agreements include conditional payment terms tied to approval timelines for the weight loss indication of semaglutide injection.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300199•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Hybio Pharmaceutical publishes news
Free account required • Unsubscribe anytime